Sofosbuvir and peginterferon/ribavirin demonstrates virologic response rates in G3 hep C patients

26 abril 2015

New results demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/q6gnvFtMpWQ/150425215740.htm

Volver